Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR 1,427.70
-21.00 (-1.45%)
Nov 21, 2025, 3:30 PM IST
Concord Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
Net Income | 3,239 | 3,716 | 3,081 | 2,401 | 1,749 | 2,349 | Upgrade |
Depreciation & Amortization | 640.36 | 543.61 | 535.43 | 538.94 | 498.96 | 273.69 | Upgrade |
Other Amortization | 0.13 | 0.13 | 0.49 | 1.39 | 1.55 | 1.54 | Upgrade |
Loss (Gain) From Sale of Assets | 2.16 | 2.25 | -0.12 | 0.94 | 0.34 | - | Upgrade |
Loss (Gain) From Sale of Investments | -237.51 | -222.64 | -140.65 | -37.17 | -52.3 | -69.86 | Upgrade |
Loss (Gain) on Equity Investments | -40.66 | 13.22 | -33.71 | -19.59 | 36.38 | 4.49 | Upgrade |
Provision & Write-off of Bad Debts | 16.43 | 17.84 | 6.69 | 0.92 | -3.46 | 4.59 | Upgrade |
Other Operating Activities | -218.28 | 81.91 | 17.31 | 96.59 | 71.19 | -7.52 | Upgrade |
Change in Accounts Receivable | -434.9 | -1,708 | -786.6 | -430.97 | -527.69 | 65.01 | Upgrade |
Change in Inventory | -258.53 | -317.13 | 43.61 | -172.27 | -415.12 | -423.77 | Upgrade |
Change in Accounts Payable | 71.25 | 220.89 | -112.87 | 98.81 | 365.35 | -225.1 | Upgrade |
Change in Other Net Operating Assets | -334.54 | 96.54 | 44.06 | -18.42 | 356.91 | -303.77 | Upgrade |
Operating Cash Flow | 2,445 | 2,445 | 2,655 | 2,460 | 2,081 | 1,668 | Upgrade |
Operating Cash Flow Growth | -18.34% | -7.89% | 7.91% | 18.19% | 24.77% | 7.73% | Upgrade |
Capital Expenditures | -1,149 | -1,112 | -856.89 | -1,451 | -1,555 | -2,042 | Upgrade |
Sale of Property, Plant & Equipment | 2.85 | 1.99 | 1.75 | 0.25 | 0.56 | - | Upgrade |
Investment in Securities | -179.33 | -598.08 | -718.69 | -184.76 | 395.22 | 88.64 | Upgrade |
Other Investing Activities | 109.3 | 107.95 | 27.73 | 55.85 | 41.4 | 1.07 | Upgrade |
Investing Cash Flow | -1,216 | -1,600 | -1,546 | -1,580 | -1,118 | -1,952 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 50.99 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 519.72 | Upgrade |
Total Debt Issued | - | - | - | - | - | 570.71 | Upgrade |
Short-Term Debt Repaid | - | - | - | -43.37 | - | - | Upgrade |
Long-Term Debt Repaid | - | -67.45 | -265.04 | -265.96 | -266.56 | -202.41 | Upgrade |
Total Debt Repaid | -10.43 | -67.45 | -265.04 | -309.33 | -266.56 | -202.41 | Upgrade |
Net Debt Issued (Repaid) | -10.43 | -67.45 | -265.04 | -309.33 | -266.56 | 368.3 | Upgrade |
Common Dividends Paid | -1,119 | -915.39 | -714.53 | -535.64 | -705.21 | -57.06 | Upgrade |
Other Financing Activities | -0.88 | -4.84 | -12.58 | -7.23 | -22.26 | - | Upgrade |
Financing Cash Flow | -1,131 | -987.68 | -992.15 | -852.19 | -994.02 | 311.24 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | -0 | - | -14.29 | - | Upgrade |
Net Cash Flow | 98.88 | -142.38 | 116.43 | 28.32 | -44.77 | 27.36 | Upgrade |
Free Cash Flow | 1,297 | 1,333 | 1,798 | 1,009 | 526.36 | -373.59 | Upgrade |
Free Cash Flow Growth | -33.12% | -25.83% | 78.14% | 91.72% | - | - | Upgrade |
Free Cash Flow Margin | 11.53% | 11.11% | 17.68% | 11.83% | 7.38% | -6.06% | Upgrade |
Free Cash Flow Per Share | 12.37 | 12.75 | 17.18 | 9.65 | 5.03 | -3.57 | Upgrade |
Cash Interest Paid | 3.1 | 6.33 | 26.5 | 39.58 | 53.15 | - | Upgrade |
Cash Income Tax Paid | 1,138 | 1,094 | 1,033 | 702.77 | 607.85 | 751.77 | Upgrade |
Levered Free Cash Flow | 1,044 | 926.14 | 1,177 | 505.95 | 188.91 | -831.9 | Upgrade |
Unlevered Free Cash Flow | 1,046 | 929.45 | 1,193 | 534.14 | 223.18 | -827.74 | Upgrade |
Change in Working Capital | -956.72 | -1,708 | -811.8 | -522.86 | -220.55 | -887.63 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.